Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.

Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.

Publication date: Sep 21, 2023

This study aimed to determine whether the introduction of anti-SARS-CoV-2 vaccines and the dominance of the omicron variant had a significant impact on the outcome of COVID-19 in patients with systemic autoimmune rheumatic diseases (SAIRDs). Using data entered to the Greek Rheumatology Society COVID-19 registry, we investigated the incidence of hospitalization and death due to COVID-19, during the successive periods of the pandemic according to the prevalent strain (wild-type, Alpha, Delta, Omicron) in vaccinated and unvaccinated patients. Variables independently associated with hospitalization and death were explored using multivariate regression analyses, while Kaplan-Meier curves were used to depict survival data. From August 2020 until June 30, 2022, 456 cases (70. 2% females) of COVID-19 with a mean age (+/- SD) of 51. 4 +/- 14. 0 years were reported. In unvaccinated patients, the proportions of hospitalization and death were 24. 5% and 4%, compared to 12. 5% and 0. 8% in the vaccinated group (p 

Open Access PDF

Concepts Keywords
Greek Anti-SARS-CoV-2 vaccine
June Autoimmune rheumatic disease
Rheumatic COVID-19
Vaccinated Mortality
Omicron variant


Type Source Name
disease VO vaccination
disease MESH COVID-19
disease MESH rheumatic diseases
disease MESH death
disease VO vaccinated
disease VO unvaccinated
disease MESH Long Covid
disease MESH infection
drug DRUGBANK Rituximab
disease MESH cardiovascular disease
disease MESH pulmonary disease
disease VO vaccine
disease MESH immunocompromised patients
disease VO population
disease VO report
disease MESH musculoskeletal diseases
disease MESH morbidities
disease MESH idiopathic inflammatory myopathies
disease MESH polymyalgia rheumatica
disease MESH arteritis
disease MESH syndromes
disease MESH sarcoidosis
disease VO dose
disease VO vaccine dose
disease MESH re infection
disease VO immunization
disease VO ANOVA
disease MESH arthritis
disease MESH erythema
disease MESH psoriatic arthritis
disease MESH axial spondyloarthritis
disease MESH vasculitis
disease IDO cell
disease MESH hypertension
disease MESH obesity
drug DRUGBANK Trestolone
drug DRUGBANK Coenzyme M
drug DRUGBANK Ritonavir
drug DRUGBANK Adenosine 5′-phosphosulfate
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Methotrexate
drug DRUGBANK Leflunomide
drug DRUGBANK Azathioprine
drug DRUGBANK Sulfasalazine
drug DRUGBANK Apremilast
drug DRUGBANK Cyclophosphamide
drug DRUGBANK Mycophenolic acid
drug DRUGBANK Ciclosporin
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH systemic lupus erythematosus
pathway KEGG Systemic lupus erythematosus
disease MESH antiphospholipid syndrome
disease MESH systemic sclerosis
disease MESH connective tissue disease
drug DRUGBANK Belimumab
disease MESH Diabetes mellitus
disease MESH Malignancy
disease VO effectiveness
drug DRUGBANK Esomeprazole
disease MESH vascular diseases
disease VO time
pathway REACTOME Reproduction
drug DRUGBANK Polyethylene glycol
disease VO vaccine effectiveness
disease VO effective
disease MESH Piedra
disease MESH breakthrough infections
disease IDO country

Original Article

(Visited 1 times, 1 visits today)